Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $9.60.

FULC has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday. Royal Bank Of Canada increased their price objective on Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 30th. HC Wainwright raised Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $4.00 to $12.00 in a research report on Tuesday, July 29th. Finally, Wall Street Zen raised Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 26th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC grew its holdings in Fulcrum Therapeutics by 865.0% during the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after purchasing an additional 308,854 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Fulcrum Therapeutics during the first quarter valued at $425,000. Exome Asset Management LLC grew its holdings in Fulcrum Therapeutics by 143.0% during the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after purchasing an additional 405,538 shares during the period. XTX Topco Ltd bought a new position in Fulcrum Therapeutics during the first quarter valued at $144,000. Finally, Nuveen LLC bought a new position in Fulcrum Therapeutics during the first quarter valued at $441,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $8.99 on Friday. The company has a market cap of $486.27 million, a P/E ratio of -7.37 and a beta of 2.93. The stock has a 50 day simple moving average of $7.45 and a two-hundred day simple moving average of $6.32. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $9.88.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, research analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.